Covid-19 has demonstrated to investors that “you lose money in all sectors if you don’t prioritise access to healthcare”, according to the Access to Medicine Foundation, which says the issue is rising up the investor agenda as a result.
Today sees the launch of the Access to Medicine Index 2021, a ranking of the largest 20 pharmaceutical companies on their action to improve access to medicine in 106 countries. GSK, Novartis and Johnson & Johnson hold the top three places.
The report seeks to help investors deepen their understanding of the risk to companies around access to medicine issues, and inform engagement with firms on issues such as pricing of medicine and research and development.
Speaking to RI, Mara Lilley, Investment Engagement Manager at the Access to Medicine Foundation, said that this year there was more appreciation from investors that “no-one can assume access to healthcare is a far away issue” and that overlooking the …